Viral membrane fusion protein

The term "Tumor cell membrane fusion/lysis via viral replication" does not refer to a single molecular target or receptor. Instead, it describes a **therapeutic strategy** that exploits the ability of certain viruses—especially those engineered for oncolytic virotherapy—to infect tumor cells. These viruses use their **viral membrane fusion proteins** ("fusogens") to merge their envelope with the tumor cell's plasma membrane, allowing entry and subsequent replication within the cancer cell. This process can lead directly to **tumor cell lysis** through non-apoptotic mechanisms and may also promote immune recognition by exposing tumor antigens after lysis[4]. The actual molecular targets are diverse classes of **viral fusogenic glycoproteins**, which are essential for mediating this process across all enveloped viruses[1][2]. These proteins are major targets for antiviral drugs and vaccines but are not themselves human therapeutic targets like receptors or enzymes. In summary, "Tumor cell membrane fusion/lysis via viral replication" is an approach rather than a discrete molecule or receptor; its core components are various **viral fusogenic proteins**, which do not have a universal canonical name or abbreviation applicable across all contexts.

Other names

Viral fusion proteinFusion glycoproteinFusogenEnvelope fusion protein

Inhibition of membrane fusion between virus and host cell Blockade of conformational changes in the viral envelope glycoprotein required for entry[1]